TNBC is the most aggressive subtype, associated with higher metastasis rate and tumor grade [4, 5] and lacks the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2, ruling out endocrine and trastuzumab therapies as treatment options [5]. Here, PGR is linked to neoplasm.